AVTR vs. ILMN, RVTY, WAT, BIO, BIO.B, HOLX, LH, BAX, DGX, and ALNY Should you be buying Avantor stock or one of its competitors? The main competitors of Avantor include Illumina (ILMN), Revvity (RVTY), Waters (WAT), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Hologic (HOLX), Laboratory Co. of America (LH), Baxter International (BAX), Quest Diagnostics (DGX), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "medical" sector.
Avantor (NYSE:AVTR ) and Illumina (NASDAQ:ILMN ) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Avantor has higher revenue and earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
95.1% of Avantor shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 1.3% of Avantor shares are held by company insiders. Comparatively, 0.2% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Avantor has a net margin of 3.79% compared to Illumina's net margin of -28.71%. Avantor's return on equity of 13.01% beat Illumina's return on equity.
Illumina received 911 more outperform votes than Avantor when rated by MarketBeat users. Likewise, 65.71% of users gave Illumina an outperform vote while only 63.64% of users gave Avantor an outperform vote.
In the previous week, Avantor had 1 more articles in the media than Illumina. MarketBeat recorded 14 mentions for Avantor and 13 mentions for Illumina. Avantor's average media sentiment score of 1.20 beat Illumina's score of 0.79 indicating that Avantor is being referred to more favorably in the media.
Avantor presently has a consensus price target of $26.71, indicating a potential upside of 7.24%. Illumina has a consensus price target of $164.65, indicating a potential upside of 50.08%. Given Illumina's higher probable upside, analysts plainly believe Illumina is more favorable than Avantor.
Avantor has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Summary Avantor beats Illumina on 14 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AVTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
